Search results
Showing 31 to 45 of 47 results for bortezomib multiple myeloma
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
Past technology appraisal appeals and decisions
Awaiting development Reference number: GID-TA12030 Expected publication date: TBC
Discontinued Reference number: GID-TA10171
We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.
Discontinued Reference number: GID-TA10502
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma...
Discontinued Reference number: GID-TA10568
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.